Sun Pharmaceutical Industries, a leading Indian pharmaceutical manufacturer, has announced its acquisition of Organon & Co, a prominent U.S.-based healthcare company, in an all-cash transaction valued at $11.75 billion. This strategic move represents a significant expansion of Sun Pharma's international footprint and portfolio, enabling the company to strengthen its presence in developed markets and accelerate growth in specialized therapeutic areas. The deal underscores the growing trend of cross-border consolidation within the global pharmaceutical industry.

Summary auto-generated by AI from the original publisher's content. Editorial standards.